The role of pregnancy-associated plasma protein-a level in the first trimester of pregnancy and clinical outcome in an urban referral centre

Background: Estimation of serum PAPP-A levels studied predictability for adverse perinatal outcome. This case control study tries to establish the association between low PAPP-A levels among the pregnant woman and adverse maternal foetal outcome.Methods: This is an case-control study during 2017-2018 in the women delivered at Department of OBG at Mehta Hospitals. Women delivered in the labour room  had a first trimester screening of PAPP-A level were explained, taken informed consent, questionnaire which include detailed antenatal history, mode of delivery and baby data.  Depending upon outcome, the subjects are classified as case group or control group, out of the study sample of 264 subjects, 88 patients who had complications were taken as cases and 176 patients with no complications taken as control were undertaken.Results: Low PAPP-A level (<0.5 MoM) showed high incidence of PIH and preeclampsia, followed by IUGR and Preterm. PAPP-A level >0.5 MoM, normal outcome is more than the adverse outcome. The difference in the PAPP-A levels is statistically significant. In women with low PAPP A level, low birth weight found statistically significant when compared with <0.5 PAPP A level. The sensitivity of PAPP A levels in identifying the complicated outcomes was 17.04%.The specificity was 98.85%. The positive predictive value of predicting the complications was 88.23% and negative predictive value of 70.44%.Conclusions: The low PAPP-A levels confirmed during first trimester of pregnancy is associated with adverse maternal and foetal outcome such as PIH, preeclampsia, preterm, IUGR and LBW.

Corrección de medianas de la fracción beta libre de gonadotrofina coriónica humana y proteína plasmática A del embarazo del primer trimestre para una muestra de población mexicana / Medians correction of free beta subunit of human chorionic gonadotropin and pregnancy-associated plasma protein-A during the first trimester for a Mexican population sample

Resumen Objetivo: determinar si en una muestra de población mexicana la distribución de los marcadores séricos del primer trimestre difiere del modelo de riesgos de The Fetal Medicine Foundation y calcular los factores de corrección necesarios para un desempeño adecuado de la prueba. Materiales y Métodos: estudio descriptivo y transversal en el que se midieron las concentraciones de beta-hCG-libre y proteína plasmática A del embarazo en sueros maternos del primer trimestre, por ensayo de electroquimioluminiscencia aprobado por la Fetal Medicine Foundation. Se obtuvieron los múltiplos de mediana ajustados por el algoritmo de la Fetal Medicine Foundation (astraia). Para describir la distribución de cada marcador y probar su diferencia estadística con la media 0.000, se hizo su transformación a log10 ideal mediante la prueba de t para una muestra. Además, se describen las distribuciones de los múltiplos de mediana por características del embarazo y lote de reactivo. Resultados: en 1008 sueros, el log10 MoM global fue de -0.121 ± 0.2706 para beta-hCG-libre y -0.049 ± 0.2372 para proteína plasmática A del embarazo. Conclusiones: en esta muestra poblacional mexicana las distribuciones de beta-hCG-libre y proteína plasmática A del embarazo difieren de las esperadas para población similar a la hispana europea. Se recomienda aplicar los respectivos factores de corrección de 0.756 y de 0.893 para las medianas del algoritmo.

Abstract Objective: To determine whether first trimester serum markers distribution on a Mexican population sample differ from The Fetal Medicine Foundation (FMF) risks model, and to calculate the necessary correction factors for accurate test performance. Materials and Method: Transverse descriptive study, Free-beta-hCG and PAPP-A were measured on unselected first trimester maternal sera using FMF approved electrochemiluminescence assay, the adjusted MoM were obtained from FMF algorithm (astraia); they were log10 transformed to describe each marker distribution and to test their statistical difference with the 0.000 ideal mean by one sample t-test. MoM distributions for pregnancy characteristics and reagent lot are additionally described. Results: On 1008 sera, the overall adjusted log10MoM was -0.121 ± 0.2706 SD for Free-beta-hCG and -0.049 ± 0.2372 SD for PAPP-A; these distributions differed significantly from tåzhe expected by FMF risks model. Conclusions: Free-beta-hCG and PAPP-A distributions on this Mexican population sample differ from expected for population similar to Hispanic European, median correction factors of 0.756 MoM and of 0.893 MoM, respectively, are recommended for the algorithm.

The concentration of the amniotic fluid angiogenin and interleukin-6 in the pregnancy with elevated maternal serum human chorionic gonadotropin during the second trimester / 대한산부인과학회잡지

OBJECTIVE: This study is to measure the level of concentration of angiogenin, a cause of potent neovascularization and a marker of ischemia, and of interleukin-6 (IL-6), an indicator of acute inflammation, in the amniotic fluid of patients with elevated maternal serum free beta-hCG level during the second-trimester. MATERIALS AND METHODS: Twenty patients with elevated maternal serum free beta-hCG level (>2.5 MoM) at double screening test of Down syndrome were compared with the controlled group (<2.0 MoM). This study includes singleton gestation, gestational age of 14-18 weeks, and has no evidence of fetal structural and chromosomal anomalies. The levels of amniotic angiogenin and IL-6 were measured by enzyme-linked immunosorbent assay (ELISA) method. Data were analyzed by Mann-Whitney U test. p value <0.05 was considered significant. RESULTS: Amniotic angiogenin levels in the studied group were much lower than those in the controlled group (p<0.05), whereas the difference of IL-6 levels between the two groups was not significant. Nine studied patients delivered small for gestational age infants, but only one controlled patient (p<0.05) had the same infant. Other variables of perinatal outcome were not different between the two groups. CONCLUSION: That amniotic fluid angiogenin levels are significantly lower in patients with elevated maternal serum free beta-hCG suggests an inadequate angiogenesis. Elevated maternal serum free beta-hCG levels correlate with fetal growth restriction. IL-6 values in both groups have no significant difference.

Clinical usefulness of serum alpha-FP and free beta-hCG levels in midtrimester / 대한산부인과학회잡지

OBJECTIVE: The aim of this study was to evaluate the detection rate of the chromosomal abnormalities by screening of maternal serum alpha-FP, free beta-hCG in midtrimester and to evaluate the association of elevated free beta-hCG with neonatal & pregnancy outcome. METHODS: From October 1995 to December 1999, We studied 8,304 pregnant women who delivered in Asan Medical Center. We measured the levels of serum alpha-FP and free beta-hCG in the midtrimester. We reviewed high Down risk group, high NTD risk group and numerous cases of chromosomal abnormalities, retrospectively. To evaluate the association of elevated free beta-hCG with neonatal & pregnancy outcome, we reviewed birth weight, apgar score, gestational age at delivery, presence of PIH or fetal growth restriction. RESULTS: Two hundred ninety eight (3.6%) women were screened as high Down risk pregnancy, 61 (0.7%) women were screened as high NTD risk pregnancy. In the high risk group of chromosomal abnormalities, there were 13 cases of various chromosomal abnormalites, including of six Down syndrome baby. In the low risk group, there were two (0.02%) Down syndrome baby and 8 cases of other chromosomal abnormality. By using maternal serum alpha-FP, free beta-hCG in mid-trimester, 68% of the detection rate of chromosomal abnormalites and 4.1% of false positive rate was reported. The detection rate of Down syndrome is 75% (6/8) and 3.5% of false positive rate, 0.02% of false negative rate were reported. In the aspect of pregnancy outcome, when the free beta-hCG more than 2.5MOM, there were more numerous preterm delivery (8.2% vs 3.8%), IUGR (4.6% vs 1.7%), lower 1 min apgar score than 7 (6.4% vs 2.7%). CONCLUSION: Maternal serum alpha-FP, free beta-hCG is at least useful method as Double markers screening method for fetal chromosomal abnormalites and maybe elevated free beta-hCG level can be useful marker of poor pregnancy outcome such as PIH, low birth weight or preterm delivery.

The efficacy of nuchal translucency with free beta-hCG, PAPP-A as a screening test for detection of chromosomal anomaly in the first trimester of pregnancy / 대한산부인과학회잡지

OBJECTIVES: The aim of this study is to determine the efficacy of nuchal translucency in combination with free beta-hCG, PAPP-A in the first trimester screening for chromosomal anomaly in general population. METHODS: Between April 1998 and December 1999, we evaluated 263 pregnant women undergoing first trimester screening test for fetal chromosomal anomaly using nuchal translucency combined with free beta-hCG, PAPP-A. We confirmed the pregnancy outcomes through chorionic villi sampling, amniocentesis or term delivery. We excluded 15 pregnant women because of their obscure pregnancy outcomes. Statistical analysis was considered significant when P value was lower than 0.05. RESULTS: With a risk cut-off of 1 in 400, 24 pregnancies(9.7%) of 248 cases were screen positive and 224 pregnancies(90.3%) were screen negative. 2 cases of Down syndrome and 1 case of Turner syndrome were detected in screen positive group. No chromosomal anomalies were detected in screen negative group. CONCLUSION: In this study, 8.57% of false positive rate and 12.5% of positive predictive value were obtained in the first trimester screening for chromosomal anomaly using nuchal translucency and serum markers.

Evaluation of the Dual Test using PAPP-A and Free beta-hCG in First Trimester as a Prenatal Screening Test for Down Syndrome / 대한임상병리학회지

BACKGROUND: Dual test has been reported to be a useful first trimester screening test for Down syndrome and is comprised of measuring two serum parameters; pregnancy associated plasma protein A(PAPP-A) and free beta chorionic gonadotrophin(beta-hCG). This study was performed to investigate the distribution of these two parameters in Korean pregnant women and compare its significance with that of Triple test which is a second trimester screening test and being more commonly used in Korea. METHODS: For the Dual test, serum PAPP-A and free beta-hCG were each measured by radioimmunoassay(AMERLEX-M kitTM) in 2,526 first-trimester pregnant women. Triple test was done in 7,007 second-trimester pregnant women. RESULTS: The median value of PAPP-A was 9.3, 12.5, 18.1 and 26.6 IU/mL, and that of free beta-hCG was 47.8, 35.4, 29.4 and 29.3 nmol/L in 10th, 11th, 12th and 13th gestational week, respectively. The Dual test was positive in 7.8%(198/2,526), while the Triple test was positive in 3.0%(208/7,007). Among 87 Dual test positive cases, Down syndrome was diagnosed in three cases(3.5%), while 71 Triple test positive cases, seven cases(9.9%) were Down syndrome. Among 1,316 cases who had both the Dual and Triple test, 1,300(98.8%) were both negative, and two(0.2%) were both positive, showing 99% of concordance rate. CONCLUSIONS: These results showed a possibility that the Dual test could be used as a valuable first-trimester screening test for Down syndrome in our country.